CIM6P/IGF-2 Receptor Ligands Reverse Deficits in Angelman Syndrome Model Mice.
Emmanuel Cruz, Giannina Descalzi, Adam Steinmetz and 3 others
PMID 33108069WHAT IT FOUND
In mice with Angelman syndrome, a single injection of IGF-2 or M6P reversed memory, motor, and repetitive behavior deficits.
IGF-2 also reduced seizures. These findings are preclinical and have not been tested in humans.
Key findings
01Subcutaneous injection of IGF-2 or M6P reversed deficits in memory retention and flexibility in Angelman syndrome model mice.
02Both ligands reversed motor deficits, specifically hindlimb clasping and rotarod performance, with effects persisting for days.
03IGF-2, but not M6P, significantly decreased the frequency and severity of audiogenic seizures and reversed marble-burying impairments.
STILL TO COME
How it was doneWhat they found
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
This is a preclinical study in mice; no human patients were involved. Only a single acute dose was tested, whereas human treatment would likely require chronic administration. The mechanisms of action for the observed behavioral improvements are not known. The study did not assess long-term safety or efficacy of repeated injections.
Declared interests
The study was supported by N.I.H. Extramural and Non-U.S. Gov't grants. No commercial conflicts of interest are reported in the provided text.
The easy way to misread this
Do not interpret these results as evidence that IGF-2 or M6P injections are effective treatments for Angelman syndrome in humans. The study was conducted exclusively in mice, and the safety and efficacy of these ligands in human patients have not been established.